Translational Regenerative Medicine Market Forecast 2019-2029

トランスレーショナル再生医療の世界市場予測2019-2029

◆タイトル:Translational Regenerative Medicine Market Forecast 2019-2029
◆商品コード:VGN906141
◆調査・発行会社:visiongain
◆発行日:2019年2月
◆ページ数:334
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:産業未分類
◆販売価格オプション(消費税別)
Sigle UserGBP3,499 ⇒換算¥524,850見積依頼/購入/質問フォーム
Departmental/Five UserGBP3,899 ⇒換算¥584,850見積依頼/購入/質問フォーム
Site LicenseGBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"トランスレーショナル再生医療の世界市場予測2019-2029"について調査・分析し、レポートサマリー、市場の促進要因、抑制要因、市場動向、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、市場環境分析、研究開発パイプライン分析、主要企業分析、結論などの情報をお届けいたします。

The Global Translational Regenerative Medicine market is estimated to grow at a CAGR of 23.3% in the first half of the forecast period. Stem cell therapies accounted for the majority of the revenue in the market with an estimated market share of 57.7% in 2018.How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new report you will find 334-page report and you will receive 119 tables and 106 figures – all unavailable elsewhere.
The 334-page report provides clear detailed insight into the Global Translational Regenerative Medicine market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Global Translational Regenerative Medicine market forecasts from 2019-2029
• Global Translational Regenerative Medicine submarket forecasts from 2019-2029 covering:
• Stem Cell Therapies
• Tissue Engineered Products
• Gene Therapies
This study discusses the late-state clinical trials and pipeline as well as market drivers and restraints of each submarket.
• Translational Regenerative Medicine regional and national market forecasts from 2019-2029, covering:
• North America: US, Canada
• Europe: Germany, France, UK, Italy, Spain, Rest of Europe
• Asia-Pacific: China, Japan, India, Rest of Asia-Pacific
• Latin America: Brazil, Mexico, Rest of Latin America
• Middle East & Africa: GCC Countries, South Africa, Rest of Middle East & Africa

Each regional market is further segmented by sector.
• Forecasts from 2019-2029 of the selected leading products in the Global Translational Regenerative Medicine market:
• Osteocel Plus
• Trinity ELITE
• TEMCELL /Prochymal
• Apligraf
• Dermagraft
• Epifix
• ReCell
• Neovasculgen
• Glybera (alipogene tiparvovec)
• IMLYGIC (talimogene laherparepvec)
• Assessment of the leading companies in the Global Translational Regenerative Medicine market:
• Athersys, Inc.
• Avita Medical
• AxoGen, Inc.
• MEDIPOST Co., Ltd.
• NuVasive
• Astellas Pharma
• Organogenesis Holdings Inc.
• Osiris Therapeutics, Inc.
• Pharmicell Co., Ltd.
• Regenerys Ltd.
• Takeda Pharmaceutical Company Limited
• uniQure N.V. N.V.
• Vericel Corporation
• Information on current developments, current advancements and current key approvals in the field of translational regenerative medicine market.
• SWOT and Porter’s Five Force analysis of the translational regenerative medicine market

【レポートの目次】

1. Report Overview
1.1 Global Translational Regenerative Medicine Market Overview
1.2 Overview of Findings
1.3 Structure of the Report
1.4 Global Translational Regenerative Medicine Market Segmentation
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8. Who is This Report For?
1.9 Methodology
1.10 Associated Visiongain Reports
1.11 About Visiongain

2. Introduction to Translational Regenerative Medicine
2.1 What is Regenerative Medicine?
2.1.1 Translational Regenerative Medicine – From Bench to Bedside
2.2 Translational Regenerative Medicine – Market Breakdown
2.2.1 Stem Cell Therapy – Marketable Differentiation and Specialisation
2.2.1.1 How Embryonic Stem Cells (ESCs) Entered the Fray
2.2.1.2 Classifying Stem Cells by Potency
2.2.1.3 Stem Cells Categories: ESCs, SSCs, iPSCs
2.2.1.4 Parthenogenetic Stem Cells: Ethical ESC-Like Cells?
2.2.1.5 Autologous vs. Allogeneic Stem Cells: Towards Universal Stem Cell Products?
2.2.2 Tissue Engineering – In Vitro Manipulation for Therapeutic Purposes
2.2.3 Gene Therapies
2.2.3.1 Harnessing Infectivity: Viral Vectors in Gene Therapy
2.3 Other Approaches to Regenerative Medicine
2.3.1 Small Molecules and Proteins – Scaffold-Based Delivery of Signalling Molecules
2.3.2 Cosmetic Applications of Regenerative Medicine
2.4 Regulation of Regenerative Medicine
2.4.1 Regulation of Regenerative Medicine Products in Europe
2.4.2 Regulation of Regenerative Medicine Products in the US
2.5 The Phases of Clinical Trials
2.6 Market Definition
2.6.1 Products Excluded from the Report

3. Translational Regenerative Medicine Market, 2019-2029
3.1 Global Translational Regenerative Medicine: Market Overview
3.1.1 Segments within the Global Translational Regenerative Medicine Market
3.2 The Global Translational Regenerative Medicine Market in 2017 and 2018
3.3 Global Translational Regenerative Medicine: Market Forecast 2019-2029
3.3.1 Market Sectors That Will Drive Translational Regenerative Medicine Growth
3.3.2 Global Translational Regenerative Medicine Market – Changing Market Shares by Sector 2019-2029
3.3.3 Global Translational Regenerative Medicine Market – Current Developments in the Field, 2016, 2017 & 2018

4. Stem Cell Therapies: Leading Applications, 2019-2029
4.1 The Global Market for Stem Cell Therapies, 2017 and 2018
4.1.1 Stem Cell Therapies: Currently Available Therapies
4.1.2 Haematopoietic Stem Cell Transplantation (HSCT)
4.1.2.1 HSCT for the Treatment of Multiple Sclerosis – A Possible Cure?
4.1.3 Stem Cell Orthobiologics
4.2 Stem Cell Therapies: Global Market Forecast 2019-2029
4.3 AlloStem (AlloSource)
4.4 Osteocel Plus (NuVasive)
4.4.1 Osteocel Plus: Sales Forecast 2019-2029
4.5 Trinity ELITE and Trinity Evolution (Orthofix)
4.5.1 Trinity ELITE and Trinity Evolution: Sales Forecast, 2019-2029
4.6 PureGen (AlphaTec Spine)
4.7 Other Approved Stem Cell Therapy Products
4.7.1 Cartistem (Medipost)
4.7.2 Cupistem (Anterogen)
4.7.3 Hearticellgram-AMI (Pharmicell)
4.7.4 TEMCELL/ Prochymal/ Remestemcel-L (Mesoblast)
4.7.4.1 TEMCELL/ Prochymal (Remestemcel-L): Sales Forecast 2019-2029
4.8 Development Pipeline for Stem Cell Therapies, 2019-2029
4.8.1 Late-Stage Pipeline for Stem Cell Therapies, 2018
4.8.1.1 StemEx and NiCord (Gamida Cell)
4.8.1.1.1 StemEx Shows Improved Survival at 100 Days – but FDA Wants Another Clinical Trial
4.8.1.2 Copper Chelator Based Technology
4.8.1.3 NiCord
4.8.1.3.1 NiCord: Gamida Cell Reaches Agreement on Phase 3 Design Outline with the FDA and EMA
4.8.1.3.2 NAM Technology Platform
4.8.1.4 Mesenchymal Precursor Cell Therapies (Mesoblast)
4.8.1.5 Adult Autologous CD34+ Cells (Baxter)
4.8.1.6 MyoCell (U.S. Stem Cell Inc.)
4.8.1.7 Adipocell (Bioheart)
4.8.1.8 Cx601 (TiGenix)
4.8.1.9 Adipose-Derived Stem Cells (Cytori Therapeutics)
4.8.1.10 Stempeucel (Stempeutics Research)
4.8.1.11 C-Cure (Cardio3 BioSciences)
4.8.1.12 Other Late-Stage Stem Cell Therapies
4.8.2 Diabetes and Stem Cell Therapy
4.8.2.1 Mesenchymal Precursor Cells (Mesoblast)
4.8.2.2 VC-01 (ViaCyte Inc)
4.8.2.2.1 Clinical Development Efforts for VC-01 for the Treatment of Diabetes
4.8.3 Cardiovascular Disease and Stem Cell Therapy
4.8.3.1 Endometrial Regenerative Cells (MediStem, Intrexon)
4.8.3.2 AMR-001 (Caladrius Biosciences)
4.8.3.3 CAP-1002 (Capricor)
4.8.4 Stem Cell Therapy in Cancer
4.8.4.1 CLT-008 (Cellerant Therapeutics)
4.8.4.2 OncoCyte/BioTime – Targeting Cancer with Gene and Stem Cell Therapy
4.8.5 Stem Cell Therapy for Central Nervous System (CNS) Conditions
4.8.5.1 NurOwn (BrainStorm Cell Therapeutics)
4.8.5.1.1 Clinical Development Efforts for NurOwn, 2015
4.8.5.2 NSI-566 (Neuralstem)
4.8.5.3 NSI-189 (Neuralstem)
4.8.5.4 MultiStem (Athersys)
4.8.5.5 PDA-001 (Cenplacel-L, Celgene)
4.8.5.6 ALD-401 (Cytomedix)
4.8.5.7 ReN001 (ReNeuron)
4.8.6 Stem Cell Therapy for Eye Diseases
4.8.6.1 MA09-hRPE (Ocata Therapeutics)
4.8.6.2 HuCNS-SC (StemCells Inc.)
4.8.6.3 Collaboration and License Agreement Between Pfizer And The London Project to Cure Blindness
4.9 ChondroCelect (TiGenix BV)
4.10 Stem Cells Therapy Market: Drivers and Restraints 2019-2029

5. Tissue Engineering Therapies: Leading Applications, 2019-2029
5.1 The Global Market for Tissue Engineered Therapies, 2017
5.1.1 Tissue Engineering Therapies: Currently Available Therapies
5.2 Tissue Engineering Therapies: Global Market Forecast 2019-2029
5.3 Tissue Engineering in Wound Repair and Healing
5.3.1 Apligraf (Organogenesis)
5.3.1.1 Apligraf: Historical Sales Analysis
5.3.1.2 Apligraf: Sales Forecast 2019-2029
5.3.2 BioDfence and BioDfactor (BioD)
5.3.3 CureXcell (MacroCure)
5.3.4 Dermagraft (Organogenesis)
5.3.4.1 Dermagraft (Organogenesis): Sales Forecast 2019-2029
5.3.5 Epifix (MiMedx)
5.3.5.1 Epifix (MiMedx): Sales Forecast 2019-2029
5.3.6 Epicel (Vericel)
5.3.7 Grafix (Osiris Therapeutics)
5.3.8 MySkin and CyroSkin (Regenerys)
5.3.9 ReCell (Avita Medical)
5.3.9.1 ReCell (Avita Medical): Sales Forecast 2019-2029
5.4 Tissue Engineering for Cartilage Repair
5.4.1 Autologous Chondrocyte Implantation (ACI)
5.4.2 Carticel (Vericel Corp.)
5.4.3 ChondroCelect (TiGenix, Sobi Partners)
5.4.4 DeNovo NT (Zimmer)
5.4.5 MACI (Vericel Corp.)
5.5 Other Available Tissue Engineering Therapies
5.5.1 Autologous Cultured Cell and Tissue Products (Japan Tissue Engineering Co.)
5.5.2 Gintuit (Organogenesis)
5.5.3 LAVIV (azficel-T), (Fibrocell Science)
5.5.4 Acellular Tissue Engineering Products
5.6 Tissue Engineering: Development Pipeline, 2019-2029
5.6.1 Pipeline Products for Autologous Chondrocyte Implantation
5.6.2 Tissue Engineering for Skin
5.6.3 Tissue Engineering for Liver Diseases
5.6.3.1 Extracorporeal Bio-Artificial Liver Therapy (Vital Therapies)
5.6.4 Tissue Engineering for Cardiovascular Disease
5.6.5 Tissue Engineering for Eye Diseases
5.7 Future Prospects for Organ Transplantation and Tissue Engineering
5.8 Tissue Engineered Products Market: Drivers and Restraints 2019-2029

6. Gene Therapies: Leading Applications, 2019-2029
6.1 The Global Market for Gene Therapies, 2017
6.2 Gene Therapies: Global Market Forecast 2019-2029
6.3 Currently Available Gene Therapy Products
6.3.1 Gendicine (Benda Pharmaceutical)
6.3.2 Oncorine (Shanghai Sunway Biotech)
6.3.3 Neovasculgen (Human Stem Cells Institute)
6.3.3.1 Neovasculgen (HSCI): Sales Forecast 2019-2029
6.3.4 Glybera (UniQure N.V.)
6.3.5 IMLYGIC (talimogene laherparepvec) – (Amgen)
6.3.5.1 Clinical Trials and Development Efforts for IMLYGIC
6.3.5.2 Talimogene Laherparepvec (IMLYGIC) – Sales Forecast 2019-2029
6.4 Development Pipeline for Gene Therapies, 2019-2029
6.4.1 Late-Stage Pipeline Gene Therapies, 2018
6.4.1.1 Collategene (beperminogene perplasmid, AMG0001) – (AnGes MG/Vical)
6.4.1.2 ProstAtak (AdV-tk) – (Advantagene)
6.4.1.3 Trinam (taberminogene vadenovec) – (Ark Therapeutics)
6.4.1.4 AAV2-hRPE65v2 (Spark Therapeutics)
6.4.1.5 CG0070 (Cold Genesys)
6.4.2 Gene Therapy for Use in the Treatment of Diabetes
6.4.3 Gene Therapy Directed at Oncology Indications
6.4.4 Gene Therapy Directed at Neurological Diseases
6.4.5 Gene Therapy Directed at Tackling Haemophilia B
6.5 Gene Therapy Market: Drivers and Restraints 2019-2029

7. Leading National Markets 2019-2029
7.1 The Translational Regenerative Medicine Market by Region
7.2 World Translational Regenerative Medicine Market: Regional Forecast 2019-2029
7.2.1 How Will Regional Market Shares Change to 2029?

8. North America Translational Regenerative Medicine Market 2019-2029
8.1. US Translational Regenerative Medicine Market: Market Forecast 2019-2029
8.1.1 US Translational Regenerative Medicine Market: Market Drivers and Restraints, 2019-2029
8.1.2 US Translational Regenerative Medicine Market: Market Forecast 2019-2029
8.1.3 The Regulatory Framework for Regenerative Medicine in the US
8.1.4 The Impact of Ethical and Regulatory Reluctance to Embryonic Stem Cell Research and Its Impact on Funding
8.1.5 How Is the Ending of Patenting for Human Gene Products Affecting the Regenerative Medicine Market in the US?
8.2. Canada Translational Regenerative Medicine Market: Trends and Developments

9. Europe Translational Regenerative Medicine Market 2019-2029
9.1 Europe: A Fragmented Regenerative Medicine Market
9.1.1 European Regenerative Medicine Market: Market Drivers and Restraints, 2019-2029
9.1.2 European Regenerative Medicine Market: Market Forecast 2019-2029
9.2 Europe Markets: Changing Market Shares by Country, 2019-2029
9.2.1 Europe‘s Unitary Patent System and Its Impact on the Future of Regenerative Medicine in the Region
9.2.2 Regulation of Regenerative Medicine in the European Union
9.3 Germany
9.3.1 German Translational Regenerative Medicine Market: Market Forecast 2019-2029
9.4. France Translational Regenerative Medicine Market Forecast 2019-2029
9.5. U.K.
9.5.1. U.K. Translational Regenerative Medicine Market Forecast 2019-2029
9.5.2 Regulation of Stem Cell Research in the UK
9.6 Italy
9.6.1 Italy Translational Regenerative Medicine Market Forecast 2019-2029
9.7. Spain Translational Regenerative Medicine Market Forecast 2019-2029
9.8. Rest of Europe Translational Regenerative Medicine Market Forecast 2019-2029
9.8.1 Russia: Rising Interest in Regenerative Medicine Research

10. Asia-Pacific Translational Regenerative Medicine Market 2019-2029
10.1 Accommodating Regulatory Landscape Aiding Rapid Product Commercialisation
10.1.1 Asia-Pacific Regenerative Medicine Market: Market Drivers and Restraints, 2019-2029
10.1.2 Asia-Pacific Regenerative Medicine Market: Market Forecast 2019-2029
10.3 China: Encouraging Stem Cell R&D
10.3.1 Government Intervention into TRM Research in China
10.3.2 Regulation of Stem Cell Research in China
10.3.3 Commercialisation of Gene Therapy and Tissue Engineering Products in China
10.3.4 Medical Tourism Impacting Market Growth for Regenerative Medicine in China
10.3.5 China Translational Regenerative Medicine Market Forecast 2019-2029
10.4. Japan: Difficulty in Translating Research into Commercialisation
10.4.1 Research Funding: A Major Determinant of Growth in Japan‘s Regenerative Medicine
10.4.2 Government Interventions in Promoting Stem Cell Research in Japan
10.4.3 Regulation of Regenerative Medicine in Japan
10.4.4 Accelerating Approvals of Regenerative Medicine Products in Japan
10.4.5 Japanese Translational Regenerative Medicine Market Forecast 2019-2029
10.5. India: An Emerging Market for Regenerative Medicine
10.5.1 Efforts in Stem Cell Research in India
10.5.2 Unclear Guidelines Hindering Progression of Gene Therapy Research in India
10.5.3 India Translational Regenerative Medicine Market Forecast 2019-2029
10.6. Rest of Asia-Pacific Translational Regenerative Medicine Market: Trends and Developments
10.6.1 Australia: Encouraging Translational Regenerative Medicine
10.6.2 South Korea: First to Approve Stem Cell Treatments
10.6.3 A Regeneration in South Korea‘s Stem Cell Research Efforts
10.6.4. Rest of Asia-Pacific Translational Regenerative Medicine Market Forecast 2019-2029

11. Latin America Translational Regenerative Medicine Market 2019-2029
11.1 Brazil
11.1.1 Brazil Translational Regenerative Medicine Market Forecast 2019-2029
11.1.1.1 Stem cell initiatives in Brazil
11.1.1.2 Stem cell regulation & strengths, weaknesses & opportunities in Brazil
11.2. Mexico Translational Regenerative Medicine Market: Trends and Developments
11.2.1 Stem cell initiatives in Mexico
11.2.2 Stem cell regulation & strengths, weaknesses & opportunities in Mexico
11.3. Rest of Latin America Translational Regenerative Medicine Market: Trends and Developments

12. Middle East & Africa Translational Regenerative Medicine Market 2019-2029
12.1. GCC Countries Translational Regenerative Medicine Market Forecast 2019-2029
12.2. South Africa Translational Regenerative Medicine Market Forecast 2019-2029
12.3. Rest of Middle East & Africa Translational Regenerative Medicine Market Forecast 2019-2029

13. Leading Companies in the Translational Regenerative Medicine Market, 2019-2029
13.1 Introduction to the Leading Companies
13.2. Athersys, Inc.
13.2.1 Overview
13.2.2 Financial Overview
13.2.3 Athersys: Pipeline Analysis, 2018
13.2.3.1 MultiStem Technology – Potential Treatment for a Range of Diseases
13.2.4 Recent Transactions Summary
13.3. Avita Medical
13.3.1 Overview
13.3.2 Financial Overview
13.3.3 Avita Medical: Regenerative Medicine Portfolio, 2018
13.3.4 Avita Medical: Pipeline Analysis, 2018
13.3.5 Recent Transactions Summary
13.4. AxoGen, Inc.
13.4.1 Overview
13.4.2 Financial Overview
13.4.3 AxoGen, Inc.: Regenerative Medicine Portfolio, 2018
13.4.4 AxoGen, Inc.: Pipeline Analysis, 2018
13.4.5 Recent Transactions Summary
13.5. MEDIPOST Co., Ltd.
13.5.1 Overview
13.5.2 Financial Overview
13.5.3 MEDIPOST Co., Ltd.: Regenerative Medicine Portfolio, 2018
13.5.4 MEDIPOST Co., Ltd.: Pipeline Analysis, 2018
13.5.5 Recent Transactions Summary
13.6. NuVasive
13.6.1 Overview
13.6.2 Financial Overview
13.6.3 NuVasive: Regenerative Medicine Portfolio, 2018
13.6.4 NuVasive: Pipeline Analysis, 2018
13.6.5 Recent Transactions Summary
13.7. Astellas Pharma
13.7.1 Overview
13.7.2 Financial Overview
13.7.3 Astellas Pharma (Ocata Therapeutics): Pipeline Analysis, 2018
13.7.3.1 Retinal Pigment Epithelial Cell Therapy
13.7.3.2 Ocata‘s Other Therapeutic Platforms
13.7.4 Recent Transactions Summary
13.8. Organogenesis Holdings Inc.
13.8.1 Overview
13.8.2 Organogenesis Holdings Inc.: Regenerative Medicine Portfolio, 2018
13.8.3 Organogenesis Holdings Inc.: Pipeline Analysis, 2018
13.8.4 Recent Transactions Summary
13.9. Osiris Therapeutics, Inc.
13.9.1 Overview
13.9.2 Financial Overview
13.9.3 Osiris Therapeutics, Inc.: Regenerative Medicine Portfolio, 2018
13.9.4 Osiris Therapeutics, Inc.: Pipeline Analysis, 2018
13.9.5 Recent Transactions Summary
13.10. Pharmicell Co., Ltd.
13.10.1 Overview
13.10.2 Financial Overview
13.10.3 Pharmicell Co., Ltd.: Pipeline Analysis, 2018
13.11. Regenerys Ltd.
13.11.1 Overview
13.11.2 Regenerys Ltd.: Regenerative Medicine Portfolio, 2018
13.11.3 Regenerys Ltd.: Pipeline Analysis, 2018
13.11.4 Recent Transactions Summary
13.12 Takeda Pharmaceutical Company Limited
13.12.1 Overview
13.12.2 Financial Overview
13.12.3 Takeda Pharmaceutical Company Limited (TiGenix): Pipeline Analysis, 2018
13.12.4 Recent Transactions Summary
13.13 uniQure N.V. N.V.
13.13.1 Overview
13.13.2 Financial Overview
13.13.3 UniQure N.V.: Pipeline Analysis, 2018
13.13.4 Recent Transactions Summary
13.14 Vericel Corporation
13.14.1 Overview
13.14.2 Financial Overview
13.14.3 Vericel Regenerative Medicine Portfolio, 2018
13.14.4 Vericel Corporation: Pipeline Analysis, 2018
13.14.4.1 The ixCELL-DCM Clinical Trial
13.14.5 Recent Transactions Summary

14. Qualitative Analysis of the Translational Regenerative Medicine Market, 2019-2029
14.1 Market Factors Influencing the Translational Regenerative Medicine Market
14.2 SWOT Analysis of the Translational Regenerative Medicine Market
14.2.1 Strengths
14.2.1.1 Improvements in Regulatory Frameworks
14.2.1.2 Advancements in General Cellular and Tissue Research Aiding Regenerative Medicine
14.2.1.3 Strong Support from Governments in Multiple Regions
14.2.1.4 Increasing Ease of Product Commercialisation and Market Access
14.2.2 Weaknesses
14.2.2.1 The High Price of Translational Regenerative Medicine Products May Restrain Market Growth
14.2.2.2. Lack of Funding from Venture Capital
14.2.2.3 The Intrinsic Lack of Standardisation is a Burden to Scaling up Manufacturing
14.2.2.4 Successful Commercialisation of TRM Products Requires New Business Models
14.2.3. Opportunities
14.2.3.1 3D Bioprinting and Other Technologies May Enable Rapid Scale-Up
14.2.3.2 Medical Tourism May Stimulate Standardisation and Drive Market Growth
14.2.3.3 Disruptive Translational Regenerative Medicine Therapies Can Create New Markets
14.3.4. Threats
14.3.4.1 Ethical Concerns Limiting R&D in Regenerative
14.3.4.2 Difficulty Establishing Evidence Base for Long-Term Efficacy of TRM Therapies
14.3.4.3 Rate of Scientific Progress – A Major Determinant of TRM Market Growth
14.3.4.4 Restraints on Reimbursement May Slow Growth
14.4 Porter‘s Five Force Analysis of the Translational Regenerative Medicine Market, 2019-2029
14.4.1 Threat of New Entrants
14.4.2 Threat of Substitutes
14.4.3 Power of Suppliers
14.4.4 Power of Buyers
14.4.5 Rivalry among Competitors

15. Conclusions
15.1 Overview of Current Market Conditions and Market Forecast, 2019-2029
15.2 Stem Cell Therapies Will Remain as the Dominant Submarket
15.3 Leading Regions in the Translational Regenerative Medicine Market in 2018
15.4 R&D Pipeline Products Crucial to Future Market Growth
15.5 What Does the Future Hold for Regenerative Medicine?

Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

List of Tables
Table 2.1 European Union Definitions of Regenerative Medicine Products, 2019
Table 2.2 Potency and Source of Stem Cells, 2019
Table 2.3 Germ Layers and Their Associated Types of Cells and Organs, 2019
Table 2.4 Major Types of Stem Cells and Their Properties, 2019
Table 2.5 Terminology for Stem Cell Donor-Types, 2019
Table 2.6 Clinical Trial Phases, 2019
Table 3.1 The Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Sector, 2017 and 2018
Table 3.2 Global Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 3.3 Global Translational Regenerative Medicine Market by Sector: CAGR (%), 2019-2023, 2023-2029, 2019-2029
Table 3.4 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2018, 2023 and 2029
Table 3.5 The Global Translational Regenerative Medicine Market: Current Developments in the Field, 2016, 2017 & 2018
Table 4.1 Selected Stem Cell Products Currently Available on The Market, 2018
Table 4.2 Stages of Osteogenesis, 2018
Table 4.3 Global Stem Cell Therapies Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
Table 4.4 Osteocel Plus Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
Table 4.5 Trinity ELITE Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
Table 4.6 TEMCELL / Prochymal Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
Table 4.7 Stem Cell Therapy Pipeline: Therapies in Development, Clinical Trials
Table 4.8 Stem Cell Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2018
Table 5.1 Selected Tissue Engineering Products Currently Available on the Market, 2018
Table 5.2 Global Tissue Engineering Therapies Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
Table 5.3 Apligraf Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
Table 5.4 Dermagraft Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
Table 5.5 Epifix Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
Table 5.6 ReCell Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
Table 5.7 Tissue Engineering Pipeline: Therapies in Development, Clinical Trials
Table 5.8 Vital Therapies: Extracorporeal Bio-Artificial Liver Therapy Clinical Trials, 2018
Table 6.1 Currently Available Gene Therapy Products, 2018
Table 6.2 Global Gene Therapies Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
Table 6.3 Neovasculgen Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
Table 6.4 Glybera Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
Table 6.5 Amgen: Gene Therapy Clinical Trials, 2018
Table 6.6 Talimogene Laherparepvec (IMLYGIC) Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
Table 6.7 Gene Therapy Pipeline: Therapies in Development, Clinical Trials
Table 6.8 Gene Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2018
Table 6.9 Advantegene: Gene Therapy Clinical Trials, 2017
Table 6.10 Spark Therapeutics: Gene Therapy Clinical Trials, 2018
Table 6.11 Recent Developments in Gene Therapy for Use in Diabetes
Table 6.12 Gene Therapy Products in the Development Pipeline for Neurological Diseases, 2018
Table 7.1 Global Translational Regenerative Medicine Market by Region: Revenue ($m), 2017 and 2018
Table 7.2 Global Translational Regenerative Medicine Market Forecast by Sector: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 7.3 Global Translational Regenerative Medicine Market by Region: CAGR (%), 2019-2023, 2023-2029, 2019-2029
Table 7.4 Global Translational Regenerative Medicine Market by Region: Market Share (%), 2017, 2023, 2029
Table 8.1 North America Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2017, 2023 and 2029
Table 8.2 North America Translational Regenerative Medicine Market Forecast by Sector: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 8.3 North America Translational Regenerative Medicine Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 8.4 US Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 8.5 Canada Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 9.1 Europe Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2017, 2023 and 2029
Table 9.2 Europe Translational Regenerative Medicine Market by Country/Sub-region: Revenue ($m) and Market Share (%), 2017
Table 9.3 Europe Translational Regenerative Medicine Market Forecast by Sector: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 9.4 Europe Translational Regenerative Medicine Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 9.5 Europe Translational Regenerative Medicine Market by Country/Sub-region: CAGR (%), 2019-2023, 2023-2029, 2019-2029
Table 9.6 Germany Translational Regenerative Medicine Market Forecast, 2017-2029 ($m, AGR %, CAGR %)
Table 9.7 France Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 9.8 U.K. Translational Regenerative Medicine Market Forecast: Revenues ($m, AGR %, CAGR %), 2017-2029
Table 9.9 Italy Translational Regenerative Medicine Market Forecast: Revenues ($m, AGR %, CAGR %), 2017-2029
Table 9.10 Spain Translational Regenerative Medicine Market Forecast: Revenues ($m, AGR %, CAGR %), 2017-2029
Table 9.11 Rest of Europe Translational Regenerative Medicine Market Forecast: Revenues ($m, AGR %, CAGR %), 2017-2029
Table 10.1 Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2017, 2023 and 2029
Table 10.2 Asia-Pacific Translational Regenerative Medicine Market Forecast by Sector: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 10.3 Asia-Pacific Translational Regenerative Medicine Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 10.4 China Translational Regenerative Medicine Market Forecast: Revenues ($m, AGR %, CAGR %), 2017-2029
Table 10.5 Japan Translational Regenerative Medicine Market Forecast: Revenues ($m, AGR %, CAGR %), 2017-2029
Table 10.6 India Translational Regenerative Medicine Market Forecast: Revenues ($ m), AGR (%), CAGR (%), 2017-2029
Table 10.7 Rest of Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 11.1 Latin America Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2017, 2023 and 2029
Table 11.2 Latin America Translational Regenerative Medicine Market Forecast by Sector: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 11.3 Latin America Translational Regenerative Medicine Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 11.4 Brazil Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 11.5 Mexico Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 11.6 Rest of Latin America Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 12.1 Middle East & Africa Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2017, 2023 and 2029
Table 12.2 Middle East & Africa Translational Regenerative Medicine Market Forecast by Sector: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 12.3 Middle East & Africa (MEA) Translational Regenerative Medicine Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 12.4 GCC Countries Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 12.5 South Africa Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 12.6 Middle East & Africa (MEA) Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
Table 13.1. Athersys, Inc.: Overview, 2019
Table 13.2 Athersys, Inc.: Revenue ($m), AGR (%), 2013-2017
Table 13.3 Athersys: Regenerative Medicine Clinical Trials, 2018
Table 13.4 Avita Medical: Overview, 2019
Table 13.5 Avita Medical: Revenue ($m), AGR (%), 2014-2018
Table 13.6 Avita Medical: Regenerative Medicine Clinical Trials, 2018
Table 13.7. AxoGen, Inc.: Overview, 2019
Table 13.8 AxoGen, Inc.: Revenue ($m), AGR (%), 2013-2017
Table 13.9 AxoGen, Inc.: Regenerative Medicine Clinical Trials, 2018
Table 13.10. MEDIPOST Co., Ltd.: Overview, 2019
Table 13.11 MEDIPOST Co., Ltd.: Revenue ($m), AGR (%), 2013-2017
Table 13.12 MEDIPOST Co., Ltd.: Regenerative Medicine Clinical Trials, 2018
Table 13.13. NuVasive.: Overview, 2019
Table 13.14 NuVasive: Revenue ($m), AGR (%), 2013-2017
Table 13.15 NuVasive: Regenerative Medicine Clinical Trials, 2018
Table 13.16. Astellas Pharma.: Overview, 2019
Table 13.17 Astellas Pharma: Revenue ($m), AGR (%), 2013-2017
Table 13.18 Astellas Pharma (Ocata Therapeutics): Regenerative Medicine Clinical Trials, 2018
Table 13.19. Organogenesis Holdings Inc.: Overview, 2019
Table 13.20 Organogenesis Holdings Inc.: Regenerative Medicine Clinical Trials, 2018
Table 13.21. Osiris Therapeutics, Inc.: Overview, 2019
Table 13.22 Osiris Therapeutics, Inc.: Revenue ($m), AGR (%), 2013-2017
Table 13.23 Osiris Therapeutics, Inc.: Regenerative Medicine Clinical Trials, 2018
Table 13.24. Pharmicell Co., Ltd.: Overview, 2019
Table 13.25 Pharmicell Co., Ltd.: Revenue ($m), AGR (%), 2013-2017
Table 13.26. Regenerys Ltd.: Overview, 2019
Table 13.27 Regenerys Ltd.: Regenerative Medicine Clinical Trials, 2018
Table 13.28. Takeda Pharmaceutical Company Limited.: Overview, 2019
Table 13.29 Takeda Pharmaceutical Company Limited: Revenue ($m), AGR (%), 2013-2017
Table 13.30 Takeda Pharmaceutical Company Limited: Regenerative Medicine Clinical Trials, 2018
Table 13.31. UniQure N.V..: Overview, 2019
Table 13.32 UniQure N.V.: Revenue ($m), AGR (%), 2013-2017
Table 13.33 UniQure N.V.: Regenerative Medicine Clinical Trials, 2018
Table 13.34. Vericel Corporation.: Overview, 2019
Table 13.35 Vericel Corporation: Revenue ($m), AGR (%), 2013-2017
Table 13.36 Vericel Corporation: Regenerative Medicine Clinical Trials, 2018
Table 14.1 SWOT Analysis of the Global Translational Regenerative Medicine Market, 2019-2029
Table 15.1 Global Translational Regenerative Medicine Market Forecast: Revenue ($m), and CAGR (%), 2017, 2023 and 2029
Table 15.2 Global Translational Regenerative Medicine Market by Sector: CAGR (%), 2017, 2023, 2029
Table 15.3 Global Translational Regenerative Medicine Market by Region: CAGR (%), 2017, 2023, 2029
Table 15.4 Global Translational Regenerative Medicine Market: Products in Late Stage Development, 2018

List of Figures
Figure 1.1 Global Translational Regenerative Medicine Market Segmentation Overview
Figure 2.1 Brief History of Stem Cell Research, 1900-2019
Figure 2.2 Examples of FDA-Approved Tissue Engineering Products
Figure 2.3 Brief History of Tissue Engineering, 1900-2019
Figure 2.4 Brief History of Gene Therapy, 1970-2019
Figure 3.1 The Global Translational Regenerative Medicine Market Forecast by Sector: Revenue ($m), 2017 and 2018
Figure 3.2 The Global Translational Regenerative Medicine Market Forecast: Revenue ($m), 2017 and 2018
Figure 3.3 Global Translational Regenerative Medicine Market Forecast: Revenue ($m), AGR (%), 2017-2029
Figure 3.4 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2019-2023
Figure 3.5 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2023-2029
Figure 3.6 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2019-2029
Figure 3.7 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2018, 2023 and 2029
Figure 3.8 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2018
Figure 3.9 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2023
Figure 3.10 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2029
Figure 4.1 Global Stem Cell Therapies Market Forecast: Revenue ($m) and AGR (%), 2019-2029
Figure 4.2 Osteocel Plus Sales Forecast: Revenue ($m) and AGR (%), 2019-2029
Figure 4.3 Trinity ELITE Sales Forecast: Revenue ($m) and AGR (%), 2019-2029
Figure 4.4 TEMCELL / Prochymal Sales Forecast: Revenue ($m) and AGR (%), 2019-2029
Figure 4.5 Stem Cell Therapies: Drivers and Restraints
Figure 5.1 Global Tissue Engineering Therapies Market Forecast: Revenue ($m) and AGR (%), 2019-2029
Figure 5.2 Apligraf Sales Forecast: Revenue ($m) and AGR (%), 2019-2029
Figure 5.3 Dermagraft Sales Forecast: Revenue ($m) and AGR (%), 2019-2029
Figure 5.4 Epifix Sales Forecast: Revenue ($m) and AGR (%), 2019-2029
Figure 5.5 ReCell Sales Forecast: Revenue ($m) and AGR (%), 2019-2029
Figure 5.6 Tissue Engineered Therapy: Drivers and Restraints
Figure 6.1 Global Gene Therapies Market Forecast: Revenue ($m) and AGR (%), 2019-2029
Figure 6.2 Neovasculgen Sales Forecast: Revenue ($m) and AGR (%), 2019-2029
Figure 6.3 Glybera Sales Forecast: Revenue ($m) and AGR (%), 2019-2029
Figure 6.4 Talimogene Laherparepvec (IMLYGIC) Sales Forecast: Revenue ($m) and AGR (%), 2019-2029
Figure 6.5 Gene Therapy: Drivers and Restraints
Figure 7.1 World Translational Regenerative Medicine Market: Revenues ($m) by Region, 2017
Figure 7.2 World Translational Regenerative Medicine Market: Revenues ($m) by Region, 2018
Figure 7.3 Global Translational Regenerative Medicine Market Forecast: Revenue ($m), AGR (%), 2017-2029
Figure 7.4 World Translational Regenerative Medicine Market: Market Shares (%) by Regional Market, 2017
Figure 7.5 World Translational Regenerative Medicine Market: Market Shares (%) by Regional Market, 2023
Figure 7.6 World Translational Regenerative Medicine Market: Market Shares (%) by Regional Market, 2029
Figure 8.1 North America Translational Regenerative Medicine Market Forecast: Revenues ($ m), AGR (%), 2017-2029
Figure 8.2 North America Translational Regenerative Medicine Market: Market Shares (%) by Country, 2017
Figure 8.3 North America Translational Regenerative Medicine Market: Market Shares (%) by Country, 2023
Figure 8.4 North America Translational Regenerative Medicine Market: Market Shares (%) by Country, 2029
Figure 8.5 North America Translational Regenerative Medicine: Drivers and Restraints
Figure 8.6 U.S. Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 8.7 Canada Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 9.1 Europe Translational Regenerative Medicine: Drivers and Restraints
Figure 9.2 Europe Translational Regenerative Medicine Market: Revenues ($m) by Country/Sub-region, 2017
Figure 9.3 Europe Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 9.4 Europe Translational Regenerative Medicine Market: Market Shares (%) by Country, 2017
Figure 9.5 Europe Translational Regenerative Medicine Market: Market Shares (%) by Country, 2023
Figure 9.6 Europe Translational Regenerative Medicine Market: Market Shares (%) by Country, 2029
Figure 9.7 Germany Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 9.8 France Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 9.9 U.K. Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 9.10 Italy Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 9.11 Spain Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 9.12 Rest of Europe Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 10.1 Asia-Pacific Translational Regenerative Medicine: Drivers and Restraints
Figure 10.2 Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 10.3 Asia-Pacific Translational Regenerative Medicine Market: Market Shares (%) by Country, 2017
Figure 10.4 Asia-Pacific Translational Regenerative Medicine Market: Market Shares (%) by Country, 2023
Figure 10.5 Asia-Pacific Translational Regenerative Medicine Market: Market Shares (%) by Country, 2029
Figure 10.6 China Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 10.7 Japan Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 10.8 India Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 10.9 Rest of Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 11.1 Latin America Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 11.2 Latin America Translational Regenerative Medicine Market: Market Shares (%) by Country, 2017
Figure 11.3 Latin America Translational Regenerative Medicine Market: Market Shares (%) by Country, 2023
Figure 11.4 Latin America Translational Regenerative Medicine Market: Market Shares (%) by Country, 2029
Figure 11.5 Brazil Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 11.6 Mexico Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 11.7 Rest of Latin America Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 12.1 Middle East & Africa (MEA) Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 12.2 Middle East & Africa Translational Regenerative Medicine Market: Market Shares (%) by Country, 2017
Figure 12.3 Middle East & Africa Translational Regenerative Medicine Market: Market Shares (%) by Country, 2023
Figure 12.4 Middle East & Africa Translational Regenerative Medicine Market: Market Shares (%) by Country, 2029
Figure 12.5 GCC Countries Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 12.6 South Africa Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 12.7 Rest of MEA Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
Figure 13.1 Athersys, Inc.: Revenue ($m), AGR (%), 2013-2017
Figure 13.2 Athersys, Inc.: Business Segment Revenue Share (%), 2017
Figure 13.3 Avita Medical: Revenue ($m), AGR (%), 2014-2018
Figure 13.4 Avita Medical: Business Segment Revenue Share (%), 2017
Figure 13.5 AxoGen, Inc.: Revenue ($m), AGR (%), 2013-2017
Figure 13.6 MEDIPOST Co., Ltd.: Revenue ($m), AGR (%), 2013-2017
Figure 13.7 MEDIPOST Co., Ltd.: Business Segment Revenue Share (%), 2017
Figure 13.8 NuVasive: Revenue ($m), AGR (%), 2013-2017
Figure 13.9 NuVasive: Business Segment Revenue Share (%), 2017
Figure 13.10 Astellas Pharma: Revenue ($m), AGR (%), 2013-2017
Figure 13.11 Astellas Pharma: Region Revenue Share (%), 2017
Figure 13.12 Osiris Therapeutics, Inc.: Revenue ($m), AGR (%), 2013-2017
Figure 13.13 Osiris Therapeutics, Inc.: Product Revenue Share (%), 2017
Figure 13.14 Pharmicell Co., Ltd.: Revenue ($m), AGR (%), 2013-2017
Figure 13.15 Takeda Pharmaceutical Company Limited: Revenue ($m), AGR (%), 2013-2017
Figure 13.16 Takeda Pharmaceutical Company Limited: Business Segment Revenue Share (%), 2017
Figure 13.17 Takeda Pharmaceutical Company Limited: Regional Revenue Share (%), 2017
Figure 13.18 UniQure N.V.: Revenue ($m), AGR (%), 2013-2017
Figure 13.19 Vericel Corporation: Revenue ($m), AGR (%), 2013-2017
Figure 13.20 Vericel Corporation: Product Revenue Share (%), 2017
Figure 14.1 Porter’s Five Force Analysis of the Translational Regenerative Medicine Market, 2019
Figure 15.1 Translational Regenerative Medicine Market Forecast by Sector: Revenue ($m), 2017-2029
Figure 15.2 Global Translational Regenerative Medicine Market Forecast: Revenue ($m) 2017, 2023, 2029
Figure 15.3 Global Translational Regenerative Medicine Drugs Market by Sector: Market Share (%), 2018
Figure 15.4 Global Translational Regenerative Medicine Drugs Market by Sector: Market Share (%), 2023
Figure 15.5 Global Translational Regenerative Medicine Drugs Market by Sector: Market Share (%), 2029
Figure 15.6 The Global Translational Regenerative Medicine Market Forecast by Region: Revenue (US$ Bn), 2017, 2023, 2029

★調査レポート[トランスレーショナル再生医療の世界市場予測2019-2029] ( Translational Regenerative Medicine Market Forecast 2019-2029 / VGN906141) 販売に関する免責事項
[トランスレーショナル再生医療の世界市場予測2019-2029] ( Translational Regenerative Medicine Market Forecast 2019-2029 / VGN906141) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆